Defends Pfizer in federal class action antitrust litigations with respect to Celebrex, accusing the company of delaying entry of generic competition for Celebrex through alleged fraud on the US patent office and sham patent litigation. In re Celebrex Antitrust Litigation (E.D. Va.).
Defends Pfizer in federal consolidated class action antitrust litigations and a state court action brought by the West Virginia Attorney General with respect to Lipitor, accusing the company of delaying entry of generic competition for Lipitor through alleged fraud on the US patent office and sham patent litigation, a sham FDA citizen petition and a reverse payment settlement agreement. In re Lipitor Antitrust Litig., 46 F. Supp. 3d 523 (D.N.J. 2014); State of West Virginia v. Pfizer, Inc., et al. (Cir. Ct., Mason Cty., W.V.).
Defends Pfizer in federal class action antitrust litigations with respect to Effexor XR, accusing the company of delaying entry of generic competition for Effexor XR through alleged fraud on the US patent office, sham patent litigation and a reverse payment settlement agreement. In re Effexor XR Antitrust Litigation, 2014 WL 4988410 (D.N.J. 2014).
Defended a major global pharmaceutical company against Robinson-Patman Act and RICO claims brought by a putative class of end payors, concerning a brand name pharmaceutical manufacturer's assistance program for reducing privately insured patients' co-pay obligations when filling a prescription.
Represented a major global pharmaceutical company in Hatch-Waxman patent litigation against generic manufacturers.
